Attovia Therapeutics (ATTO) vs Avalo Therapeutics (AVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($726.8 million vs $705.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | AVTX |
|---|---|---|
| Share price | $15.92 | $13.15 |
| Market cap | $726.77M | $705.23M |
| 1-day change | -3.05% | -3.17% |
| YTD return | — | -25.22% |
| 1-year return | — | +0.74% |
| 5-year return | — | -99.79% |
| EPS (TTM) | $-2.74 | $-4.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $24.27 |
| 52-week low | $15.75 | $12.51 |
| Distance from 52-week high | -43.14% | -45.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +165.08% | +235.21% |
| Average volume | 458.24K | 926.15K |
| Shares outstanding | 45.65M | 53.63M |
| Employees | 44 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
ATTO vs AVTX FAQ
Which is bigger, Attovia Therapeutics or Avalo Therapeutics?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $726.77M compared with $705.23M for Avalo Therapeutics (AVTX).
Are Attovia Therapeutics and Avalo Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics and Biotechnology: Pharmaceutical Preparations for Avalo Therapeutics.